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A bs tr ac t
Background
Streptococcus pneumoniae is a leading and serious coinfection in adults with human im-
munodeficiency virus (HIV) infection, particularly in Africa. Prevention of this dis-
ease by vaccination with the current 23-valent polysaccharide vaccine is suboptimal. 
Protein conjugate vaccines offer a further option for protection, but data on their 
clinical efficacy in adults are needed.
Methods
In this double-blind, randomized, placebo-controlled clinical efficacy trial, we stud-
ied the efficacy of a 7-valent conjugate pneumococcal vaccine in predominantly 
HIV-infected Malawian adolescents and adults who had recovered from document-
ed invasive pneumococcal disease. Two doses of vaccine were given 4 weeks apart. 
The primary end point was a further episode of pneumococcal infection caused by 
vaccine serotypes or serotype 6A.
Results
From February 2003 through October 2007, we followed 496 patients (of whom 44% 
were male and 88% were HIV-seropositive) for 798 person-years of observation. 
There were 67 episodes of pneumococcal disease in 52 patients, all in the HIV-infect-
ed subgroup. In 24 patients, there were 19 episodes that were caused by vaccine sero-
types and 5 episodes that were caused by the 6A serotype. Of these episodes, 5 oc-
curred in the vaccine group and 19 in the placebo group, for a vaccine efficacy of 
74% (95% confidence interval [CI], 30 to 90). There were 73 deaths from any cause 
in the vaccine group and 63 in the placebo group (hazard ratio in the vaccine group, 
1.18; 95% CI, 0.84 to 1.66). The number of serious adverse events within 14 days after 
vaccination was significantly lower in the vaccine group than in the placebo group 
(3 vs. 17, P = 0.002), and the number of minor adverse events was significantly higher 
in the vaccine group (41 vs. 13, P = 0.003).
Conclusions
The 7-valent pneumococcal conjugate vaccine protected HIV-infected adults from re-
current pneumococcal infection caused by vaccine serotypes or serotype 6A. (Current 
Controlled Trials number, ISRCTN54494731.)
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Streptococcus pneumoniae is a leading cause of death and complications in adults with human immunodeficiency virus (HIV) 
infection, particularly in sub-Saharan Africa.1,2 The 
risk of invasive pneumococcal disease is 30 to 100 
times as high in patients with HIV infection as in 
age-matched controls without such infection.3,4 
Recurrent invasive pneumococcal disease is com-
mon, with up to 25% of patients having an addi-
tional episode, predominantly reinfection, in the 
subsequent 12 months.1,5 Even among patients 
who have access to timely and effective care, the 
case fatality rate with invasive pneumococcal dis-
ease is at least 8%6 and rises to 50% in African 
populations with meningitis.7 The frequency and 
serious nature of this disease make prevention by 
vaccination desirable.
The 23-valent pneumococcal polysaccharide 
vaccine has suboptimal activity in HIV-infected 
adults and is not recommended for use in Africa.5,8 
In regions where the 23-valent vaccine is used, 
administration of the vaccine is recommended 
early in the course of HIV disease.9 Pneumococcal 
conjugate vaccines offer an alternative approach 
to preventing pneumococcal disease. The 7- and 
9-valent conjugate vaccines have been shown to be 
highly efficacious.10-13 Such vaccines are effective 
at preventing invasive pneumococcal disease in 
HIV-infected children,11 although with a lower 
efficacy and duration of effect than in children 
without HIV infection.14
There are no definitive data on the clinical 
efficacy of pneumococcal conjugate vaccines in 
adult populations. In studies involving HIV-infect-
ed adults, the vaccine was immunogenic, with 
similar quantitative antibody responses to those 
seen with the pneumococcal polysaccharide vac-
cine.15,16 Data showing improved qualitative re-
sponses, evidence of boosting with a two-dose 
regimen,16 and mucosal responses17 suggest that 
the conjugate vaccine is processed in a manner 
that differs immunologically from that of the 
polysaccharide vaccine in HIV-infected adults. 
With no validated serologic correlate of protection 
for adults, a clinical trial was required to provide 
information on the efficacy of this vaccine and 
its potential role in the management of HIV in-
fection.
We report the results of a randomized, placebo-
controlled trial of a 7-valent pneumococcal conju-
gate vaccine to prevent recurrent invasive pneu-
mococcal disease (secondary prophylaxis) in a 
cohort of predominantly HIV-infected Malawian 
adults, defined as persons 15 years of age or older 
for the purposes of this study. We first considered 
a primary-prophylaxis trial, but since the avail-
able 7-valent vaccine has low serotype coverage,18 
such a study would have required a large sample 
and a costly, complex, multisite design. We chose 
to conduct a secondary-prophylaxis study, since it 
could be performed with a smaller sample and 
more rapid accumulation of end points. Further-
more, a demonstration of efficacy in a population 
of persons who had HIV infection and a docu-
mented history of pneumococcal disease and who 
were at substantial risk for subsequent pneumo-
coccal infection would make a plausible clinical 
case for the use of the conjugate vaccine as pri-
mary prophylaxis.
Me thods
Patients
From February 2003 through May 2007, we re-
cruited patients at the Queen Elizabeth Central 
Hospital in Blantyre, Malawi, which is the main 
public hospital serving a population of approxi-
mately 1 million people. Follow-up continued until 
October 2007. We identified potential study partici-
pants on the adult medical wards through a review 
of culture analyses of blood and cerebrospinal 
f luid from which S. pneumoniae had been isolat-
ed. Patients who had survived a pneumococcal 
infection were invited to return to the study clin-
ic for screening 1 week after discharge. All pa-
tients were 15 years of age or older, resided within 
the Blantyre district, and were willing to undergo 
an HIV test. All patients provided written in-
formed consent.
To avoid possible stigmatization of the study 
as an HIV trial, we offered enrollment to all pa-
tients in whom a pneumococcal infection had 
been diagnosed, regardless of their HIV status. We 
recognized that the subgroup without HIV infec-
tion would be small (estimated at 10% of enroll-
ees19) and that the number of recurrent episodes 
of invasive pneumococcal disease was unlikely to 
be large enough for a meaningful subgroup analy-
sis. Thus, as prespecified in the protocol and 
analysis plan, the patients of primary interest were 
those with HIV infection.
Study Design
The enrollment of patients and the performance 
of laboratory investigations followed standard pro-
cedures (for details, see the Methods section in 
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the Supplementary Appendix, available with the 
full text of this article at NEJM.org). Two doses of 
vaccine were given 4 weeks apart, after which pa-
tients were requested to attend regular appoint-
ments every 3 months. Patients who moved out 
of the study area, could not be traced because of 
an inaccurate address on record, or declined fur-
ther follow-up were considered to have been lost 
to follow-up. We encouraged patients to go to 
the hospital medical ward for assessment by the 
study clinical team in the event of any illness that 
occurred between scheduled visits. Patients with 
HIV infection were encouraged to enroll in pub-
lic-sector programs of HIV care, including antiret-
roviral therapy provided at public clinics, since 
such services were set up in Blantyre over the 
course of the trial.
Patients received two doses of either a 7-valent 
pneumococcal conjugate vaccine (Prevnar, Wyeth 
Pharmaceuticals) or matching placebo (Nova Lab-
oratories). The randomization list was generated 
by a statistician who was a member of the data 
and safety monitoring board, and randomization 
was performed in permuted groups of random size 
up to 20. The blinding of vaccine administration 
is described in the Supplementary Appendix.
An episode of invasive pneumococcal disease 
was defined by the isolation of S. pneumoniae from 
a normally sterile site (i.e., blood, cerebrospinal 
fluid, or pleural fluid) in the context of a consis-
tent clinical presentation. S. pneumoniae was iden-
tified by standard methods (for details, see the 
Supplementary Appendix).
Primary and Secondary End Points
The primary end point was an episode of pneumo-
coccal disease caused by one of the vaccine sero-
types (4, 6B, 9V, 14, 18C, 19F, and 23F). During the 
course of the study and before unblinding, the 
trial’s steering group agreed to broaden the pri-
mary end point to include infection with sero-
type 6A on the basis of published data showing 
cross-protection to serotype 6A.20,21
Monitoring for Adverse Events
Adverse events were defined and recorded accord-
ing to the Harmonised Tripartite Guideline for 
Clinical Safety Data Management of the Interna-
tional Conference on Harmonisation. Grade 3 or 
4 events in the 14 days after vaccination were de-
fined as serious adverse events. Such events were 
recorded at the time of hospitalization, during a 
study visit, or by the report of a relative (in the 
case of out-of-hospital death).
To investigate possible harmful effects of vac-
cine, as seen with the use of the pneumococcal 
polysaccharide vaccine in Uganda,5 an additional 
safety end point was included (probability of death 
from pneumococcal infection). All deaths were 
reviewed by the senior study clinician and clas-
sified in terms of the perceived association with 
S. pneumoniae into four categories: definite or prob-
able, possible, unlikely, or unclassifiable owing to 
inadequate information. Since many deaths oc-
curred outside a medical setting, as is typical in 
this region, several sources of information (includ-
ing oral reports and individual health records re-
tained by relatives) were synthesized to reach a 
final decision before unblinding.
Study Oversight
A placebo-controlled efficacy trial was deemed to 
be ethically acceptable after the failure of the pneu-
mococcal polysaccharide vaccine in the earlier 
Ugandan trial.5 The study was approved by the 
ethics committee at the College of Medicine in 
Malawi and by the institutional review board at 
the Liverpool School of Tropical Medicine. The 
funders of the study (the Wellcome Trust), the 
vaccine suppliers (Wyeth Pharmaceuticals), and 
the study sponsors (the University of Liverpool) 
had no part in the study design, collection or anal-
ysis of data, or the decision to submit the manu-
script for publication. The trial’s steering com-
mittee approved the statistical-analysis plan, which 
was submitted to the committee’s chair, along with 
a cleaned data set before unblinding. All authors 
vouch for the completeness and accuracy of the 
data presented.
Statistical Analysis
To show a 60% reduction in the rate of episodes 
of invasive pneumococcal disease caused by vac-
cine serotypes (with a beta level of 0.2 and an 
alpha level of 0.05), we determined that we would 
need 402 person-years of observation to accumu-
late 42 first-event primary end points in a 1:1 as-
signment ratio. We also estimated that the rate of 
pneumococcal disease would be 250 episodes 
per 1000 person-years and that 60% of these epi-
sodes would be caused by vaccine serotypes. We 
estimated that 100 patients would be lost to fol-
low-up and 250 would die per 1000 person-years. 
Insufficient end-point accumulation before the 
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planned end date of March 2006 led the data and 
safety monitoring board to recommend continu-
ing the study until October 2007 or until the tar-
get of 42 end points had been achieved, which-
ever came first.
The primary analysis was performed according 
to the intention-to-treat principle. A per-protocol 
analysis was performed for the primary end point, 
for which the second dose of vaccine must have 
been received between 4 and 8 weeks after the first 
dose, with the at-risk period starting 2 weeks af-
ter the second vaccination. Hazard ratios for the 
first event in the vaccine group, as compared with 
the placebo group, were estimated by means of 
a Cox proportional-hazards regression model. Vac-
cine efficacy was calculated as 1 minus the haz-
ard ratio, times 100.
Adjusted hazard ratios were estimated by incor-
porating terms representing clinical stage (3 or 4, 
according to World Health Organization criteria), 
baseline CD4+  T-cell count (<200, 200 to 500, 
or >500 cells per cubic millimeter), viral load 
(<100,000 or ≥100,000 copies per milliliter), sex, 
and age (15 to 24, 25 to 34, or 35 to 75 years) 
as the most important modifiers of disease 
risk.1,5,22 When the proportional-hazards assump-
tion was violated, the Cox model was stratified 
according to the year of recruitment and the base-
line CD4+ count, and data were analyzed sepa-
rately for the first 12 months.
Data from individual records were censored on 
October 31, 2007, or the date of death or loss to 
follow-up, whichever came first. We used negative 
binomial regression models to estimate incidence-
rate ratios for multiple-event analyses. All tests 
of significance were two-sided, and a P value of 
<0.05 was considered to indicate statistical sig-
nificance. One interim analysis was planned and 
performed after 2 years for the data and safety 
monitoring board (alpha level of 0.10). Three ad-
ditional analyses were requested and performed 
on the basis of an alpha level of 0.10; the Haybit-
tle–Peto approach to significance levels was used.23 
There was no adjustment of the overall signifi-
cance level.
We report baseline findings for the whole co-
hort and efficacy results for HIV-infected patients 
only, unless otherwise indicated. We performed 
one post hoc analysis of vaccine efficacy in the 
subgroup with a CD4+ count of less than 200 cells 
per cubic millimeter in order to confirm efficacy 
in this high-risk subgroup. We report the inter-
action between the category of CD4+ count and 
the study group.
R esult s
Patients
During study enrollment, we identified 977 adults 
who had survived a confirmed episode of inva-
sive pneumococcal disease (Fig. 1). Of this group, 
496 (50.8%) were enrolled, of whom 439 (88.5%) 
had HIV infection, 465 (93.8%) received two doses 
of vaccine, and 445 (89.7%) received vaccine with-
in the window of 28 to 56 days, as specified in 
the protocol (Table 1). The reasons for not receiv-
ing two doses of vaccine were death (19 patients), 
withdrawal of consent (5 patients), and loss to 
follow-up (7 patients). The study groups were well 
balanced, except that the proportion of patients 
who reported receiving previous tuberculosis ther-
apy was larger in the placebo group.
At study termination, 273 patients were in-
cluded in the follow-up analysis; of these patients, 
239 had HIV infection, with similar numbers in 
the two study groups and an accumulated 798 
person-years of observation (682 of which were 
in patients with HIV infection). The median fol-
low-up time was 1.2 years (range, 2 days to 4.7 
years). A total of 81 patients (16.3%) were lost to 
follow-up, for a rate of 102 per 1000 person-years 
of observation (Fig. 1). More patients in the pla-
cebo group than in the vaccine group were lost 
to follow-up.
End Points
All episodes of invasive pneumococcal disease and 
pneumonia occurred in patients with HIV infec-
tion. A total of 67 episodes of invasive pneumo-
coccal disease occurred in 52 patients (98 per 1000 
person-years), including 10 episodes of meningitis, 
32 episodes of bacteremic pneumonia, 24 episodes 
of bacteremic illness with unconfirmed focus, and 
1 episode of empyema. Among these episodes, 24 
(35.8%) were caused by vaccine serotypes or the 
6A serotype (Table 2).
Of the episodes that were caused by vaccine 
serotypes or the 6A serotype (the primary end 
point), 5 occurred in vaccine recipients and 19 in 
placebo recipients (Table 3). The unadjusted vac-
cine efficacy for prevention of infection caused by 
vaccine serotypes and the 6A serotype was 74% 
(95% confidence interval [CI], 30 to 90) among 
patients with HIV infection (hazard ratio, 0.26; 
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95% CI, 0.10 to 0.70) (Table 3). Among all the pa-
tients, including those without HIV infection, the 
vaccine efficacy was 73% (95% CI, 23 to 89).
During the first 12 months after randomiza-
tion, there were 17 episodes of illness caused by 
vaccine serotypes and the 6A serotype (2 in the 
vaccine group and 15 in the placebo group), for 
an estimated efficacy of 85%. In the period after 
the first 12 months, there were 7 episodes (3 in the 
vaccine group and 4 in the placebo group), for an 
estimated efficacy of 25%. The difference between 
the two periods was not significantly heteroge-
neous (P = 0.12).
Episodes of invasive pneumococcal disease were 
most common in the subgroup of 220 patients 
who had a CD4+ T-cell count of less than 200 cells 
per cubic millimeter at baseline. In this subgroup, 
2 episodes of illness caused by vaccine serotypes 
and the 6A serotype occurred in the vaccine group, 
and 16 episodes occurred in the placebo group 
(Table 3). The vaccine efficacy in this subgroup 
was 86% (95% CI, 41 to 97; P = 0.06 for hetero-
geneity among three CD4+ categories). Of the 220 
patients in this subgroup, 19 were receiving an-
tiretroviral therapy at baseline (9 in the vaccine 
group and 10 in the placebo group).
In a multivariable analysis, the CD4+ count at 
baseline was identified as the strongest risk fac-
tor for invasive pneumococcal disease. Patients 
with a CD4+ count of less than 200 cells per cubic 
millimeter at baseline were 7.1 times as likely to 
have an invasive pneumococcal event as those 
with a CD4+ count of more than 500 (Table 4). 
A low CD4+ count was also associated with pneu-
monia from any cause and death.
Adverse Events
Minor adverse events occurred in 10.9% of patients 
in the vaccine group and 3.6% of those in the pla-
cebo group. These events included self-limiting in-
jection-site pain (35% of reported symptoms) and 
self-reported fever (28%) (Table 5 in the Supple-
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Figure 1. Enrollment and Outcomes.
Data regarding the status of human immunodeficiency virus (HIV) infection were missing for one patient in each 
study group. Both patients were considered to have HIV infection for the purpose of analysis.
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Table 1. Baseline Demographic and Clinical Characteristics and Follow-up Data.*
Variable
Vaccine
(N = 248)
Placebo
(N = 248) P Value†
At baseline
Male sex — no. (%) 106 (42.7) 111 (44.8) 0.92
Age — yr
Median 31 33 0.74
Range 16–72 15–75
Previous invasive pneumococcal disease — no. (%)
Bacteremic pneumonia 187 (75.4) 196 (79.0) 0.74
Meningitis 60 (24.2) 51 (20.6)
Other invasive syndrome 1 (0.4) 1 (0.4)
Days since previous episode of invasive pneumococcal disease
Median 19 20 0.70
Range‡ 7–1946 7–1715
History of tuberculosis — no. (%) 60 (24.2) 83 (33.5) 0.02
History of pneumonia before enrollment episode — no. (%) 99 (39.9) 116 (46.8) 0.25
Presence of HIV infection — no. (%)
Any stage 219 (88.3) 218 (87.9) 0.70
WHO clinical stage 4 42 (16.9) 45 (18.2)
Unknown status 1 (0.4) 1 (0.4)
CD4+ count at baseline — cells/mm3
Median 212 214 0.60
Range 1–1342 1–1200
Viral load at baseline — log10 copies/ml§
Median 4.9 5.0 0.16
Range 2.5–5.9 2.5–6.8
Antiretroviral therapy§¶
At baseline — no./total no. (%) 32/219 (14.6) 26/218 (11.9) 0.48
Duration — days
Median 91 84
Range 3–337 2–652
Trimethoprim–sulfamethoxazole at baseline — no./total no. (%) 20/219 (9.1) 20/218 (9.2) 1.00
At follow-up
Combined antiretroviral therapy and trimethoprim–sulfamethox-
azole at any time during study — no./total no. (%)
89/219 (40.6) 95/218 (43.6) 0.56
Second dose of vaccine received 28 to 56 days after first dose —  
no. (%)
221 (89.1) 224 (90.3) 0.62
Lost to follow-up because of withdrawal from study — no. (%) 37 (14.9) 44 (17.7) 0.28
* HIV denotes human immunodeficiency virus, and WHO World Health Organization.
† Between-group comparisons are only for patients with HIV infection. Comparisons were calculated with the use of 
Fisher’s exact test, Pearson’s chi-square test, or the Wilcoxon rank-sum test.
‡ For 13 patients, the interval between the episode of invasive pneumococcal disease and enrollment was more than  
12 months.
§  Data on viral load and receipt of antiretroviral therapy are provided only for patients with HIV infection.
¶ All patients received Triomune (Cipla Pharmaceuticals), consisting of stavudine, lamivudine, and nevirapine. For pa-
tients who had side effects, efavirenz was substituted for nevirapine in two patients, and zidovudine was substituted for 
stavudine in two patients.
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mentary Appendix). Serious adverse events were 
significantly more common in the placebo group 
(Table 6 in the Supplementary Appendix).
Rates of death were 199 per 1000 person-years 
among patients with HIV infection and 52 per 
1000 person-years among those without HIV in-
fection. Of the 136 deaths among patients with 
HIV infection, 111 (81.6%) occurred in patients 
who were not receiving antiretroviral therapy (270 
per 1000 person-years), as compared with 25 
(18.4%) among those who were receiving antiret-
roviral therapy (92 per 1000 person-years). There 
was a nonsignificant excess of deaths in vaccine 
recipients. This excess occurred 2 years or more 
after vaccination among patients with HIV infec-
tion who were not receiving antiretroviral thera-
py (Fig. 2 in the Supplementary Appendix). There 
was no between-group difference in the total num-
ber of deaths that were classified as definitely, 
probably, or possibly associated with pneumococ-
cal disease (Table 3).
Discussion
In this secondary-prophylaxis trial, a 7-valent con-
jugate pneumococcal vaccine prevented 74% of 
recurrent episodes of invasive pneumococcal dis-
ease caused by vaccine serotypes or serotype 6A 
in patients with HIV infection. The efficacy was 
highest during the first 12 months after vaccina-
tion. The vaccine also prevented pneumococcal dis-
ease in a subgroup of patients with a CD4+ T-cell 
count below 200 cells per cubic millimeter.
There was no overall effect on mortality, with 
similar proportions of patients who were alive 
and participating in follow-up at study termina-
tion in the two study groups. There was a non-
significant excess in the number of reported 
deaths in the vaccine group, specifically in the 
subgroup of patients who had a CD4+ count be-
low 500 per cubic millimeter at baseline and who 
never received antiretroviral therapy. These deaths 
were not categorized as deaths attributable to 
pneumococcal disease. The up-regulation of HIV 
by vaccines has been postulated and could theo-
retically be manifested as an increase in mortal-
ity among patients who are not receiving antiret-
roviral therapy.24 However, more patients in the 
placebo group than in the vaccine group were 
lost to follow-up, a finding that probably skewed 
the comparison of rates of death. Other investi-
gators have highlighted the problem of loss to 
follow-up in trials involving patients in low-income 
settings and have emphasized the frequency of 
death in these groups.25-28
Our study spanned a period of change in HIV 
care in Malawi with the initiation of a national 
Table 2. Invasive Pneumococcal Isolates That Were Identified in Patients, 
According to Serotype.*
Serotype
Vaccine
(N = 248)
Placebo
(N = 248)
Total
(N = 496)
no. of patients
Any serotype 29 38 67
Vaccine serotypes and serotype 6A†
All patients 5 19 24
4 1 2 3
6A 1 4 5
6B 1 2 3
9V 2 3 5
14 0 5 5
19F 0 2 2
23F 0 1 1
Other vaccine serogroup‡
All patients 2 1 3
9L 1 1 2
23 1§ 0 1
Nonvaccine serotype
All patients 22 18 40
0 0 4§ 4
1 5 2 7
3 5 0 5
7A 1 0 1
10B 0 1 1
12F 0 5 5
12B 2 0 2
15 0 1§ 1
15A 3 0 3
16¶ 3 1 4
22¶ 2 0 2
25¶ 0 1 1
33F 0 1 1
35B 0 1 1
46 1 1 2
* The 6A serotype was confirmed with the use of polymerase-chain-reaction 
analysis of the wciN region of the capsular locus.
† No invasive pneumococcal disease caused by serotype 18C was identified.
‡ A serogroup is a group of serotypes having one or more antigens in common.
§ These isolates lost viability before completion of serotyping.
¶ These isolates did not undergo factor typing.
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program for antiretroviral therapy and promotion 
of prophylaxis with trimethoprim–sulfamethox-
azole. Modification of the primary end point and 
prolongation of the study were in part a conse-
quence of these changes. The study did not have 
the power to investigate the interaction between 
the use of the pneumococcal conjugate vaccine 
and antiretroviral therapy, and refinements in the 
use of such therapy with vaccine administration 
should be investigated further — specifically, 
whether a two-dose vaccine regimen (which was 
based on evidence from immunogenicity studies 
involving HIV-infected Ugandans who were not 
receiving antiretroviral therapy16) is optimal and 
how initial and repeat doses of vaccine should 
best be administered in relation to antiretroviral 
therapy to maximize the efficacy and duration 
of protection.
This was a secondary-prophylaxis trial under-
taken in a population of predominantly HIV-
infected adults. Since there were no primary end 
points or pneumonia episodes among patients 
without HIV infection, no conclusions can be 
made about vaccine efficacy in this subgroup. By 
extension of our results in HIV-infected adults, it 
seems likely that the pneumococcal conjugate vac-
cine would also work as primary prophylaxis. The 
episodes of pneumococcal disease that occurred 
before enrollment may have primed patients for a 
response to a matching serotype, but with a rec-
ognized low risk of recurrent disease caused by the 
same serotype,1,5 the contribution of any poten-
tial priming to efficacy is probably small.
Pneumococci with vaccine serotype and sero-
type 6A antigens accounted for 50% of the epi-
sodes of invasive pneumococcal disease in the 
placebo group, and broader serotype coverage 
would be desirable. Conjugate vaccines with a 
higher valency will soon be available, but respons-
es to these vaccines should be evaluated, in par-
ticular those with different carrier proteins. HIV-
infected adults have sustained responses to toxoid 
vaccines such as those containing diphtheria an-
tigens, but this may not be true of other carrier 
Table 4. Hazard Ratios for the Primary and Secondary End Points.*
Variable Hazard Ratio (95% CI)
Primary End Point†
Any Invasive  
Pneumococcal Disease
Any Type  
of Pneumonia Death
Receipt of vaccine 0.25 (0.08–0.71) 0.74 (0.41–1.35) 0.70 (0.42–1.16) 1.38 (0.97–1.97)
Age
15–24 yr (reference)
25–34 yr 1.17 (0.28–4.78) 1.95 (0.65–5.89) 1.61 (0.62–4.22) 1.57 (0.81–3.06)
35–74 yr 0.65 (0.14–3.13) 1.37 (0.43–4.35) 1.00 (0.37–2.73) 1.43 (0.72–2.84)
Male sex 1.41 (0.52–3.85) 1.21 (0.65–2.25) 1.57 (0.94–2.64) 0.82 (0.55–1.19)
CD4+ count
<200 cells/mm3 (reference)
200–500 cells/mm3 NA 0.61 (0.34–1.13) 0.43 (0.24–0.78) 0.34 (0.22–0.53)
>500 cells/mm3 NA 0.14 (0.02–1.06) 0.29 (0.07–1.23) 0.47 (0.21–1.04)
Viral load ≥100,000 copies/ml 1.30 (0.50–3.38) 1.40 (0.75–2.62) 2.68 (1.51–4.74) 1.75 (1.20–2.57)
WHO stage 4 disease 0.94 (0.32–2.76) 1.08 (0.51–2.27) 1.30 (0.73–2.32) 2.11 (1.43–3.11)
Use of antiretroviral therapy 0.49 (0.12–2.01) 0.73 (0.31–1.73) 1.09 (0.55–2.19) 0.34 (0.19–0.58)
Use of trimethoprim–sulfamethoxazole 0.60 (0.13–2.76) 0.52 (0.20–1.34) 0.81 (0.43–1.51) 0.92 (0.59–1.43)
* Hazard ratios were derived from multivariable proportional-hazards regression models and included the use of antiretroviral therapy and 
trimethoprim–sulfamethoxazole as time-dependent covariates for the primary end points of invasive pneumococcal disease caused by vac-
cine serotypes or serotype 6A, any invasive pneumococcal disease, any type of pneumonia, and death for patients with HIV infection. Data 
regarding the baseline CD4+ cell count were missing for 31 patients (15 in the vaccine group and 16 in the placebo group), who were ex-
cluded from the analysis. NA denotes not applicable.
† When the proportional-hazards assumption was violated, the Cox model was stratified according to the year of recruitment and the baseline 
CD4+ cell count.
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proteins. The use of pneumococcal conjugate vac-
cine in HIV-infected adults will also have to be 
considered in the context of pediatric vaccination 
programs, including how such programs might 
alter the distribution of disease-causing serotypes 
in adults.29,30
We have shown that HIV-infected adults can 
have a clinically relevant response to a pneumococ-
cal conjugate vaccine, leading to protection against 
a common and serious coinfection. The ability of 
a conjugate vaccine to generate protective re-
sponses in patients with a low CD4+ count is of 
particular note and merits further study to elu-
cidate the immune mechanisms involved and 
how such mechanisms may be used to produce 
other vaccines for this population. The pneumo-
coccal conjugate vaccine provides an additional 
therapeutic intervention for improving the care of 
HIV-infected adults that is both simple and safe to 
administer, which makes its use highly relevant in 
Africa.
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